featured
Nivolumab for Advanced Refractory Biliary Tract Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Phase 2 Multi-Institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer
JAMA Oncol 2020 Apr 30;[EPub Ahead of Print], RD Kim, V Chung, OB Alese, BF El-Rayes, D Li, TE Al-Toubah, MJ Schell, JM Zhou, A Mahipal, BH Kim, DW KimFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.